Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its controlled subsidiary Changchun GeneScience Pharmaceutical Co., Ltd. — through its wholly‑owned subsidiary GENSCI Singapore Pte. Ltd. — has entered into an Asset Purchase Agreement and Supply Agreement with TWi Pharmaceuticals, Inc. (a subsidiary of Bora Pharmaceuticals Co., Ltd.,) to acquire global intellectual property rights (excluding Hungary) and Marketing Authorization Holder (MAH) rights for megestrol acetate oral suspension (brand name: 美适亚®), a therapy for cancer‑ and HIV‑associated cachexia and anorexia. The total transaction value comprises a US$30 million upfront asset transfer payment, up to US$40 million in contingent consideration, and up to US$30 million in sales milestone payments, bringing the maximum deal value to approximately US$100 million.
Contents
Deal Structure
| Item | Detail |
|---|---|
| Acquirer | GENSCI Singapore Pte. Ltd. (wholly‑owned subsidiary of GeneScience Pharmaceutical, which is a controlled subsidiary of Changchun High & New Technology, SHE: 000661) |
| Seller | TWi Pharmaceuticals, Inc. (保盛药业; subsidiary of Bora Pharmaceuticals, TPE: 6472.TW; OTCQX: BORAY) |
| Product | Megestrol acetate oral suspension (美适亚®) |
| Territory | Global (excluding Hungary) |
| Rights Transferred | Product‑specific IP (including trademarks) + MAH rights |
| Upfront Asset Transfer | US$30 million (two‑phase payment) |
| Contingent Consideration | Up to US$40 million (milestone‑based) |
| Sales Milestones | Up to US$30 million |
| Total Maximum Deal Value | ~US$100 million |
| Manufacturing | TWi Pharmaceuticals retained as long‑term contract manufacturer and supplier |
| Board Approval | 30 September 2026 (11th Board, 23rd meeting) |
| Related Party | No |
| Shareholder Approval | Not required |
Payment Structure – Two‑Phase Upfront
| Phase | Trigger | Amount |
|---|---|---|
| Phase 1 | Successful transfer of U.S. license + execution of related agreements | US$10 million |
| Phase 2 | GENSCI Singapore holds China drug registration certificate | US$20 million |
Funding Mechanism
The US$30 million MAH transfer payment will be funded by GeneScience Pharmaceutical’s capital injection into GENSCI Singapore, subject to Overseas Direct Investment (ODI) filing with Chinese regulatory authorities.
Drug Profile – Megestrol Acetate Oral Suspension
- Generic Name: Megestrol acetate oral suspension
- Brand Name: 美适亚® (Megace® ES‑equivalent formulation)
- Developer/Manufacturer: TWi Pharmaceuticals, Inc. (Taiwan)
- Drug Class: Synthetic progestin with appetite‑stimulating and anti‑cachectic properties
- Formulation: Oral suspension — optimized bioavailability compared to conventional megestrol acetate tablets
- Approved Indications:
- Anorexia in patients with Acquired Immunodeficiency Syndrome (AIDS)
- Significant weight loss due to cachexia in patients with AIDS and cancer
- China NRDL Status: Formally included in the National Reimbursement Drug List (NRDL) effective 1 January 2026
- Commercialization History: GENSCI Singapore has served as the exclusive distributor for mainland China, Hong Kong, Macau, and Singapore since 2024 under a CSO (Commercial Sales Organization) arrangement with TWi Pharmaceuticals.
Strategic Rationale – Distributor to MAH Transformation
- Vertical Integration: The transaction transforms GeneScience from a distributor/CSO into the Marketing Authorization Holder (MAH) — granting full ownership of the product’s commercial destiny across the licensed territory, including pricing strategy, label expansion, lifecycle management, and sublicensing rights.
- Cachexia Unmet Need: Cancer‑associated cachexia and HIV‑associated wasting remain significantly undertreated conditions affecting millions of patients globally. Cachexia is estimated to occur in ~50–80% of advanced cancer patients and is directly associated with reduced survival, impaired treatment tolerance, and diminished quality of life. Despite this high prevalence, limited pharmacological options are approved specifically for cachexia.
- NRDL Tailwind: The product’s inclusion in China’s NRDL effective 1 January 2026 provides an immediate reimbursement pathway for hospital prescribing, removing a major barrier to volume growth in China’s public hospital‑dominated pharmaceutical market.
- GeneScience Specialty Care Expansion: The acquisition extends GeneScience’s commercial portfolio beyond its core pediatric endocrinology franchise (anchored by recombinant human growth hormone products) into oncology supportive care and HIV/AIDS supportive care — therapeutic areas with established hospital channel overlap and specialist physician access.
- Global Scope: Acquiring global rights (excluding Hungary) provides GeneScience with international commercialization optionality — the ability to pursue regulatory filings, partnerships, or sublicensing arrangements across multiple geographies, significantly expanding the product’s revenue potential beyond the current China‑centric distribution footprint.
About TWi Pharmaceuticals / Bora Pharmaceuticals
- Founded: 2007
- Headquarters: Taiwan, China
- Parent Company: Bora Pharmaceuticals Co., Ltd. (TPE: 6472.TW; OTCQX: BORAY) — publicly listed on the Taiwan Stock Exchange
- Business Model: Dual‑engine: CDMO (Contract Development and Manufacturing Organization) + proprietary drug development and commercialization
- Focus Areas: Drug development, manufacturing, and commercialization; niche market and rare disease products in the U.S.
- Post‑Transaction Role: TWi Pharmaceuticals will continue as the contract manufacturer and long‑term supplier of megestrol acetate oral suspension for GENSCI Singapore, ensuring supply chain continuity.
Market Impact & Outlook
- Cachexia Market Opportunity: The global cachexia treatment market is estimated at several billion dollars annually, driven by the high prevalence of cancer‑associated cachexia (~3–5 million new cases per year globally) and HIV‑associated wasting. Megestrol acetate remains one of the few approved pharmacological interventions with established clinical evidence for appetite stimulation and weight gain in cachectic patients.
- China NRDL Catalyst: The product’s 1 January 2026 NRDL inclusion is expected to drive a significant uptake inflection in China’s hospital channel, where NRDL listing is a prerequisite for volume prescribing. As MAH, GeneScience will capture the full economic benefit of this reimbursement‑driven growth — compared to the distributor margin earned under the prior CSO arrangement.
- $100M Deal Economics: At a maximum total value of ~US$100 million, the transaction represents a capital‑efficient acquisition of a commercial‑stage, NRDL‑listed product with established manufacturing, regulatory approvals, and clinical acceptance. The milestone‑contingent structure (~US$70 million of the total) de‑risks the upfront investment by linking payments to regulatory and commercial achievements.
- GeneScience Revenue Diversification: The megestrol acetate acquisition adds a non‑growth‑hormone revenue stream to GeneScience’s portfolio, reducing reliance on the company’s core pediatric endocrinology franchise while leveraging existing hospital channel infrastructure in oncology and infectious disease departments.
- ODI Filing Risk: The requirement for Overseas Direct Investment (ODI) filing introduces regulatory timeline uncertainty for the Phase 1 payment. China’s ODI approval process can range from several weeks to several months, depending on the transaction size, destination jurisdiction, and regulatory workload.
- Commercialization Risk: While the product is NRDL‑listed, domestic commercialization is described as being in its early stages. Future revenue will depend on physician awareness, hospital formulary listings, competitive dynamics (including generic megestrol acetate products and emerging cachexia therapies), and policy changes in China’s reimbursement landscape.
- Global Upside Optionality: The global scope of the acquired rights (excluding Hungary) provides GeneScience with the option to pursue licensing partnerships or direct commercialization in markets where megestrol acetate oral suspension is not yet approved or where the current TWi Pharmaceuticals commercialization footprint is limited.
- Supply Chain Continuity: Retaining TWi Pharmaceuticals as the long‑term contract manufacturer ensures product quality consistency and avoids the disruption and cost of manufacturing technology transfer — a prudent approach for a commercial‑stage product with established regulatory approvals.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the transaction, regulatory approvals (including ODI filing), MAH rights transfer, and commercial expectations for megestrol acetate oral suspension. Actual results may differ materially due to risks including ODI approval timelines, satisfaction of milestone payment conditions, competitive dynamics in the cachexia treatment market, NRDL pricing and reimbursement policy changes, supply chain execution by TWi Pharmaceuticals, regulatory approvals in additional jurisdictions, and the inherent uncertainties of pharmaceutical commercialization. Investors are advised to exercise caution.-Fineline Info & Tech
